← Back to Search

Synthetic Bone Graft

NanoBone® Synthetic Bone Graft for Spinal Fusion (BONE Trial)

N/A
Recruiting
Led By Patrick Connelly, MD
Research Sponsored by Artoss Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The individual is 18 to 85 years of age.
The individual is skeletally mature.
Must not have
Patients with any known active malignancy.
Patients who are suffering from autoimmune disease.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a synthetic bone graft is as effective as a local bone graft in creating a fusion in the lumbar spine.

Who is the study for?
This trial is for adults aged 18-85 with certain spine conditions (1 or 2 level degenerative disc disease or spondylolisthesis grades 1-3) needing fusion surgery. Participants must be able to follow the study plan and not have infections, severe obesity, uncontrolled diabetes, autoimmune diseases, active cancer, mental incapacity to consent, previous lumbar fusion attempts, or other health issues that could affect results.
What is being tested?
The study tests NanoBone® Synthetic Bone Graft's effectiveness in spinal fusion compared to local bone grafts. Patients will receive NanoBone on one side of their spine and a local graft on the other as controls. The goal is to see if NanoBone can equally promote bone healing in the lumbar region.
What are the potential side effects?
While specific side effects are not listed for NanoBone®, typical risks may include pain at the graft site, inflammation, infection risk increase due to surgery and possible reaction to synthetic materials used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 85 years old.
Select...
My bones have stopped growing.
Select...
I have a diagnosis of mild to moderate spinal condition needing surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have an active cancer.
Select...
I have an autoimmune disease.
Select...
I am under 18 years old.
Select...
My diabetes is not well-controlled.
Select...
I have had chemotherapy, immunosuppressive treatment, or radiation before.
Select...
I have a condition affecting my body's collagen, bones, or mineralization.
Select...
I have been taking corticosteroids equivalent to more than 5 mg of prednisolone daily for over 2 years.
Select...
I am unable to give consent for my own medical treatment.
Select...
I have had spinal fusion surgery in the past.
Select...
I am more than 100 lbs over my ideal weight or my BMI is over 39.
Select...
I currently have an infection.
Select...
I have bone conditions that prevent spinal surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Oswestry Disability Index (ODI) 0% lowest, no disability to 100% disabled, bedridden
Radiographic Fusion
Secondary study objectives
SF-36 (Short Form 36)
Visual Analog Scale (VAS) 0-no pain to 10-worst possible pain

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single arm subject is own controlExperimental Treatment1 Intervention
Posterolateral fusion is bilateral, patients will receive the Nanobone graft on the right side of their spine and the local bone graft on their left side.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NanoBone
2012
N/A
~20

Find a Location

Who is running the clinical trial?

Artoss Inc.Lead Sponsor
3 Previous Clinical Trials
730 Total Patients Enrolled
Patrick Connelly, MDPrincipal InvestigatorUMass Memorial Health Care

Media Library

NanoBone (Synthetic Bone Graft) Clinical Trial Eligibility Overview. Trial Name: NCT04615260 — N/A
Degenerative Disc Disease Research Study Groups: Single arm subject is own control
Degenerative Disc Disease Clinical Trial 2023: NanoBone Highlights & Side Effects. Trial Name: NCT04615260 — N/A
NanoBone (Synthetic Bone Graft) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04615260 — N/A
~1 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top